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Background: In 2005, the European Medicines Agency (EMA) released guidance on 
pharmacokinetic studies in patients with hepatic impairment. This guidance describes 
the design of these studies and what information should be presented in the Summary 
of Product Characteristics (SmPC). We aim to evaluate the availability and clinical 
applicability of information on medicine use in patients with hepatic impairment in SmPCs 
and registrational dossiers of recently approved medicines.
Methods: We reviewed SmPC information on use in patients with hepatic impairment 
of 51 new medicines authorized between 2015 and 2017. Per medicine, we assessed 
the availability of nine information items derived from the EMA guidance, i.e. type of 
hepatic  disease studied; stratification by severity of hepatic impairment; influence 
of  hepatic impairment on the pharmacokinetics; safety advice in mild, moderate, and 
severe hepatic impairments; and dosing recommendation in mild, moderate, and severe 
hepatic impairments. If unavailable, the European Public Assessment Report (EPAR) and 
study report were consulted consecutively. Of available items, clinical applicability was 
assessed by labeling information as “clear” or “ambiguous”.
Results: Of 51 medicines, 15 had no pharmacokinetic study in patients with hepatic 
impairment described in their SmPC. The other 36 SmPCs contained on average seven 
of the nine information items (range 4–9). One SmPC contained all 9 items, and after 
consulting, the study reports, 11 SmPCs were complete. The item “type of hepatic disease 
studied” was available in one SmPC, though it could be retrieved in 21 study reports. 
Regarding clinical applicability, there was no medicine with all information items available 
and clearly formulated in the SmPC. A total of 12 medicines (33%) contained only clearly 
formulated information, while 24 (67%) contained at least one ambiguously formulated 
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INTRODUCTION
Patients with hepatic impairment are at risk for adverse drug 
reactions when using medicines as drug concentrations could 
increase due to pharmacokinetic (PK) changes (Delco et al., 
2005; Verbeeck, 2008). The influence of hepatic impairment on 
the PK of a medicine depends on the type and severity of the 
underlying hepatic disease (Hughes, 2008; Verbeeck, 2008). 
Cirrhosis, the advanced stage of all chronic liver diseases, has the 
largest influence on drug concentrations (Ohnhaus et al., 1982; 
Morgan and McLean, 1995; Lill et al., 2000; Verbeeck, 2008). 
Research demonstrated that nearly 30% of patients with cirrhosis 
suffer from adverse drug reactions and that almost 80% of these 
reactions was possibly preventable because inadequate dosages 
or contraindicated medicines were used (Franz et al., 2013).
The knowledge on dose adjustments and contraindications for 
medicines in patients with hepatic impairment is often based on 
the results of PK studies conducted by pharmaceutical companies. 
Realizing that information was not always generated to the same 
extent for different medicines, the European Medicines Agency 
(EMA) published a guideline on the evaluation of PK in patients 
with hepatic impairment in 2005 (European Medicines Agency, 
2005). This guideline provides recommendations on the design 
and reporting of PK studies in subjects with impaired hepatic 
function. The results from these PK studies are presented in a 
study report and discussed in the European Public Assessment 
Report (EPAR). In the Summary of Product Characteristics 
(SmPC), the safety and dosing recommendations resulting from 
the PK studies are presented to healthcare professionals.
Previous research indicated possible shortcomings in information 
provided in SmPCs on medication use in patients with hepatic 
impairment. A small study from 2002 reported that the advice in 
SmPCs was often inconsistent, unclear, and unhelpful (Anonymous, 
2001). A more recent study (2013) evaluated prescribing guidance 
on patients with hepatic impairment in USA Food and Drug 
Administration (FDA)-approved labels and reported non-specific 
dose recommendations (Chang et al., 2013). No previous study has 
assessed the quality of prescribing information in SmPCs after release 
of the EMA guideline, nor in other authorization documents. Our 
aim is therefore to evaluate the availability of specific information 
on the use of a medicine in patients with hepatic impairment in 
SmPCs, EPARs, and study reports of recently approved medicines 
and to evaluate the clinical applicability of the SmPC information.
MATERIALS AND METHODS
We included all human medicines authorized through a 
centralized procedure by the EMA from 2015 until 2017 
containing a new chemical entity. The EMA guideline 
recommends studies in patients with hepatic impairment if 
medicines are likely to be used in this population, and if hepatic 
impairment is likely to influence PK (European Medicines 
Agency, 2005). To focus our analysis on these medicines, we 
excluded single-use medicines (such as vaccines), non-systemic 
locally acting medicines, orphan medicines, and medicines that 
had a conditional approval or were approved under exceptional 
circumstances. Fixed-dose combination medicines were also 
excluded since these often contain one advice based on PK 
alterations and studies of two or more medicines which was 
difficult to incorporate in our method.
We used data from three different authorization documents: 
SmPCs, EPARs, and study reports. The SmPCs and EPARs 
were retrieved from the EMA website (https://www.ema.
europa.eu) in April and May 2018. The versions of the 
documents available on this website correspond to the most 
recently updated version. Study reports are often not or only 
partially publicly available, and individual patient data (such as 
medical histories of study subjects) are also not (yet) published 
(European Medicines Agency, 2019). If available, study reports 
were accessed through the EMA’s clinical data website (https://
clinicaldata.ema.europa.eu). The non-publicly available study 
reports and individual patient data were accessed at the Dutch 
Medicines Evaluation Board.
Per medicine, we examined the SmPC to assess whether a 
study in patients with hepatic impairment was conducted and 
described (Figure 1). If a study was described in the SmPC, the 
availability of the information and the clinical applicability were 
assessed. For medicines without a study in hepatic impairment, 
we assessed if this was explicitly mentioned in the SmPC and if a 
justification was given for its absence.
Assessment of Information Availability  
and Clinical Applicability
For the assessment of information availability, we used nine 
information items derived from the section about labeling of 
the EMA guideline (Table 1) (European Medicines Agency, 
information item (range 0–4). Items often ambiguously formulated were: “definition of mild, 
moderate, and severe hepatic impairment” (15 ambiguous SmPCs) and “safety advice in 
severe hepatic impairment” (17 ambiguous SmPCs).
Conclusion: While SmPCs contain a large part of information requested by the EMA, 
clinical applicability seems low, as it is often unclear to which specific type of hepatic 
disease patient the advice applies. This can negatively influence the practical use by 
healthcare professionals.
Keywords: medicines information, Summary of Product Characteristics (SmPC), hepatic impairment, European 
Medicines Agency (EMA) guideline, prescribing information
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2005). The guideline describes that characteristics of the 
patients included in the hepatic impairment study should be 
stated in the SmPC which we assessed by two information 
items: (Verbeeck, 2008) description of the type of hepatic 
disease studied and (Delco et al., 2005) stratification by 
severity of hepatic impairment. The third information item 
included a description of the influence of hepatic impairment 
on the PK. Concerning the remaining information items: the 
EMA states that specific recommendations should be given on 
the use (e.g., warnings, precautions) and dosing of medicines 
in patients with hepatic impairment. We incorporated this 
into one information item on the safety and one on dosing per 
severity of hepatic impairment (i.e., mild/moderate/severe) 
(six information items). A safety and dosing recommendation 
could be related to the same sentence. For example, the dosing 
recommendation “no dose adjustment needed” was also 
counted as safety recommendation since it implies that the 
medicine can be used. Four of the researchers (RW, LT, MM-S, 
KT) established the nine information items in consensus.
Per medicine, we evaluated if the nine information items 
were available in the SmPC (Table 2). For unavailable items, 
we first consulted the EPAR to assess if the item was found 
there and if still not available; the study report was checked. 
Of the available information items in the SmPC, the clinical 
applicability was assessed (Table 2). Per item, we evaluated the 
formulation of the SmPC information and labeled it as “clear” 
or “ambiguous” information. This assessment focused on the 
applicability of the advice to healthcare professionals: is it clear 
to which patients the advice applies and what the healthcare 
professional should do? As the item “the influence of hepatic 
impairment on the pharmacokinetics” is neither a description 
of the “at-risk population,” nor an instruction, this item was 
not evaluated. The clear description of the characteristics of the 
patients was assessed based on a previous study (Anonymous, 
2001). The clinical applicability of the safety and dosing 
recommendations was based on a study by Salgado et al. 
(Salgado et al., 2013). If there was no clear statement that the 
medicine can or cannot be used, the safety recommendation 
could only be labeled as “clear” information if there were safety 
actions specified for prescribers. This is in line with the EMA 
guideline: “when precaution is recommended and no specific 
dose recommendations can be given, measures to be taken by 
the prescriber (e.g., careful monitoring) should be specified.” 
(Table 1) (European Medicines Agency, 2005).
Analyses
Two authors (LT, RW) evaluated the availability and clinical 
applicability of information in the SmPCs and EPARs and 
discussed in case of discrepancies. If the authors still disagreed, 
a discussion was held with two other researchers (MM-S, KT) 
until consensus was reached. RW examined the study reports 
together with an employee of the Dutch Medicines Evaluation 
Board (MM-S). The results were analyzed using Microsoft Excel 
and reported with descriptive statistics.
RESULTS
From 2015 until 2017, the EMA authorized a total of 258 
new human medicines, and 101 were new chemical entities 
(Figure 2). We included 51 medicines in our study (Table 3). 
FIGURE 1 | Flowchart of steps followed per medicine. EMA, European 
Medicines Agency; EPAR, European Public Assessment Report; SmPC, 
Summary of Product Characteristics.
TABLE 1 | Content of section 5 “labeling issues” from the EMA guideline on the evaluation of pharmacokinetics in patients with hepatic impairment (European Medicines 
Agency, 2005).
“Specific dosing recommendations should be given in section 4.2 with cross-reference to section 5.2, and, when relevant, to sections 4.3 and/or 4.4. The 
characteristics of the subjects included in the hepatic impairment study should be stated in section 4.2, and extrapolations should not be made beyond what has 
actually been studied. Efforts should be made to describe the change in pharmacokinetics related to changes in clinical parameters like S-albumin, S-bilirubin, or 
prothrombin time (preferably expressed in terms of the international normalized ratio, INR) if a relationship has been found. Even when no posology adjustment is 
needed, this should be stated in section 4.2.
Lack of information regarding influence of hepatic impairment on the pharmacokinetics could result in a contraindication or warning, depending on the characteristics 
of the drug. When precaution is recommended and no specific dose recommendations can be given, measures to be taken by the prescriber (e.g., careful monitoring) 
should be specified.
Information regarding the influence of hepatic impairment on the pharmacokinetics should be given in the special populations subsection of section 5.2, with cross-
reference to section 4.2 if posology adjustment is needed and 4.5 if interactions may be changed. The information should include which type of hepatic disease has 
been studied, effects on parent compound and metabolites and, when relevant, include effects on protein binding and unbound exposure.
Also when pharmacokinetics in patients with hepatic impairment has not been evaluated, this information should be given in section 5.2. When relevant, information that 
hepatic impairment is unlikely to affect the pharmacokinetics to a clinically relevant extent could be included if this has been well justified.” (European Medicines Agency, 2005).
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With 27 (53%) of these, a dedicated PK study was conducted in 
patients with hepatic impairment. For nine medicines (18%), 
the SmPC described a population PK analysis, and for three 
of these nine, a dedicated PK study is currently ongoing or 
recently finished.
For 15 (29%) included medicines, no study was performed 
to assess the impact of hepatic impairment on the PK. Thirteen 
of these were monoclonal antibodies or other medicines not 
metabolized or eliminated by the liver. The remaining two are 
partly excreted in feces and have no ongoing dedicated PK study. 
Eleven of these 15 medicines also described in the SmPC that no 
study was performed, and eight provided a justification for the 
absence of a hepatic impairment study.
TABLE 2 | Method used for assessing the availability and clinical applicability of information in SmPCs.
No. Assessment of availability Assessment of clinical applicability
Is the following information item 
available?
Description Example sentences
Clear information Ambiguous information
Characteristics of patients
1. Type of hepatic disease studied Is the patient group clearly described? Is 
the term “hepatic impairment” defined?
“Patients with cirrhosis” “Patients with hepatic 
impairment”
2. Stratification by severity of hepatic 
impairment
Are the terms used to grade the severity 
of hepatic impairment defined?
“Mild hepatic impairment (Child–Pugh A)” “Mild hepatic impairment”
Influence on pharmacokinetics
3. Influence of hepatic impairment on the 
pharmacokinetics
Clinical applicability not tested
Safety recommendations
4.
5.
6.
Advice on safety in patients with:
Mild hepatic impairment
Moderate hepatic impairment
Severe hepatic impairment
Clear statement that medicines can or 
cannot be used or which safety actions 
are neededa
“Contraindicated,” “use with caution 
while monitoring …, “ “dose adjustment 
(not) needed”
“Use with caution,” “it 
is preferable to,” “not 
recommended to use”
Dosing recommendations
7.
8.
9.
Dosing recommendations in patients with:
Mild hepatic impairment
Moderate hepatic impairment
Severe hepatic impairment
Specified dose adjustment or stating 
that no dose adjustments are 
necessarya
“Adjust dose to 500 mg once daily,” 
“no dose adjustment is necessary,” 
“contraindication”
“Dose adjustment is 
necessary”
aThese items were assessed for every severity class (i.e., mild, moderate, and severe).
FIGURE 2 | Flowchart of inclusion of medicines. EMA, European 
Medicines Agency.
TABLE 3 | Characteristics of the included medicines (n = 51).
n %
Year of authorization 
2015 20 39
2016 15 29
2017 16 31
Therapeutic area 
Alimentary tract and metabolism 2 4
Blood and blood forming organs 7 14
Cardiovascular system 3 6
Dermatological drugs 1 2
Genitourinary system and reproductive hormones 1 2
Systemic hormonal preparations 1 2
Antiinfectives for systemic use 5 10
Antineoplastic and immunomodulating agents 24 47
Musculoskeletal system 1 2
Nervous system 4 8
Respiratory system 2 4
Study in patients with hepatic impairment
Dedicated pharmacokinetic study 27 53
Population pharmacokinetic analysis 9 18
No study 15 29
Total 51 100
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Availability of Information
Of the 36 medicines with a PK study, the SmPCs contained on 
average 7 of the 9 information items (range 4–9). The items 
“influence of hepatic impairment on the pharmacokinetics,” 
“safety advice in mild hepatic impairment,” and “dosing 
recommendation in mild hepatic impairment” were found in 
the SmPCs of all of these 36 medicines (Table 4). Low scoring 
items were “the type of hepatic disease studied” (n = 1, 3%) and 
“dosing recommendation in severe hepatic impairment” (n = 16, 
44%). The number of medicines with all nine information items 
available increased from one (3%) after the SmPC and EPAR 
evaluation, to 11 (31%) medicines after consulting the study 
report. Of all the study reports consulted (n = 35), 10 (29%) were 
publicly available on the EMA website.
The SmPC of one medicine described the type of hepatic disease 
studied which was cirrhosis. This information was available though 
in 21 study reports. Table 5 provides an overview of the hepatic 
diseases documented in these study reports. For five medicines, all 
patients included in the study had cirrhosis documented in their 
medical history. For the other medicines, and especially in the mild 
hepatic impairment group, the medical history of the included 
patients described a variety of hepatic diseases with and without 
cirrhosis. In some medical histories, we could not find a (chronic) 
liver disease documented.
The SmPCs of 35 (97%) medicines stratified hepatic 
impairment by severity with 27 describing the use of the Child–
Pugh classification (all dedicated PK studies). All of these 27 
medicines included patients with moderate hepatic impairment 
TABLE 4 | Availability of information on patients with hepatic impairment in authorization documents of 36 medicines.
Information item SmPC EPAR Study report
n  % n  % n  % 
Type of hepatic disease studied 1 3 1 3 22 61
Stratification by severity of hepatic impairment 35 97 35 97 35 97
Influence of hepatic impairment on the pharmacokinetics 36 100 36 100 36 100
Safety advice in mild hepatic impairment 36 100 36 100 36 100
Safety advice in moderate hepatic impairment 33 92 33 92 33 92
Safety advice in severe hepatic impairment 31 86 31 86 31 86
Dosing recommendation in mild hepatic impairment 36 100 36 100 36 100
Dosing recommendation in moderate hepatic impairment 28 78 28 78 30 83
Dosing recommendation in severe hepatic impairment 16 44 17 47 17 47
Results are expressed in number and percentage of medicines with the information item available after consulting the SmPC, EPAR, or study report. The additional information from 
the study reports in terms of type of hepatic disease studied can be found in Table 5 and the dosing recommendations in moderate hepatic impairment in the published studies of 
these medicines (Khatri et al., 2015; Gibbs et al., 2017). EPAR, European Public Assessment Report; SmPC, Summary of Product Characteristics.
TABLE 5 | Overview of hepatic diseases documented in the medical history of the included patients in the study reports of 21 medicines. Expressed in number of 
patients and stratified by severity of impairment and documentation of cirrhosis.
Documented hepatic disease Totala
(n = 368)
Mild hepatic impairment
(n = 115)
Moderate hepatic 
impairment
(n = 166)
Severe hepatic 
impairment
(n = 57)
n % n % n % n %
Cirrhosis, totalb 264 71.7 68 59.1 139 83.7 43 75.4
Alcoholic liver disease 109 41.3 24 35.3 64 46.0 15 34.9
Viral hepatitis C 139 52.7 39 57.4 72 51.8 20 46.5
Viral hepatitis B 23 8.7 7 10.3 11 7.9 2 4.7
NASH 6 2.3 3 4.4 2 1.4 1 2.3
Other 15 5.7 4 5.9 6 4.3 5 11.6
Unknown 26 9.8 2 2.9 16 11.5 5 11.6
No cirrhosis documented, totalb 104 28.3 47 40.9 27 16.3 14 24.6
Alcoholic liver disease 24 23.1 10 21.3 8 29.6 2 14.3
Viral hepatitis C 59 56.7 34 72.3 12 44.4 11 78.6
Viral hepatitis B 6 5.8 0 0.0 5 18.5 1 7.1
NASH 8 7.7 4 8.5 3 11.1 1 7.1
Other 17 16.3 5 10.6 6 22.2 1 7.1
Unknown 7 6.7 2 4.3 0 0.0 0 0.0
aThe total number of patients contains data from one additional medicine. The medical history of this medicine was not stratified by severity of impairment.
bThe individual hepatic diseases do not sum up to the total number because patients could have more than one hepatic disease documented.
NASH, non-alcoholic steatohepatitis.
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(Child–Pugh B) in their PK study, 25 included patients with 
mild hepatic impairment (Child–Pugh A), and 14 severe hepatic 
impairment patients (Child–Pugh C). The remaining eight 
medicines stratified the severity of hepatic impairment by the 
National Cancer Institute (NCI) criteria of hepatic dysfunction 
(all population PK analyses). All eight included patients with NCI 
mild hepatic impairment in their study, one included patients 
with NCI moderate hepatic impairment, and none patients with 
NCI severe hepatic impairment.
Table 6 gives an overview of the content of the safety and 
dosing recommendations, stratified by severity of hepatic 
impairment. Contraindications and dose adjustments were only 
advised in medicines subjected to a dedicated PK study.
Clinical Applicability of Information
Figure 3 shows the clinical applicability assessment of the 
SmPC information of the 36 medicines with a PK study. Table 7 
provides examples of clear and ambiguous information in 
SmPCs. When available, dosing recommendations were almost 
always formulated clearly, while information on the definition 
of mild/moderate/severe hepatic impairment (20 clear SmPCs, 
56%) and the safety advice in severe hepatic impairment (14 
clear SmPCs, 39%) was often ambiguously formulated. The 
type of hepatic disease studied was only present in one SmPC 
but ambiguously formulated. Four different wordings were used 
interchangeably (hepatic impairment, chronic liver disease, pre-
existing hepatic impairment, and hepatic cirrhosis) to define the 
“at-risk population” (Table 7). There was no medicine with all 
information items available and clearly formulated. A total of 12 
medicines (33%) contained only clearly formulated information, 
while 24 (67%) contained at least one ambiguously formulated 
information item (range 0–4).
DISCUSSION
In this study, we reviewed SmPC information on patients with 
hepatic impairment of 51 recently approved medicines and found 
that 36 described a PK study in patients with hepatic impairment 
in their SmPC. On average, 7 of 9 information items requested by 
the EMA were available in these SmPCs. Yet, safety advice or dose 
recommendations for patients with severe hepatic impairment 
were unavailable for almost 60% of evaluated medicines and/or 
ambiguously formulated. Essential information on the type of 
hepatic disease of patients included in the required PK studies 
was lacking for 35 of 36 medicines but could be retrieved for 21 
medicines in the non-publicly available part of the study report. 
Based on the documentation in the study reports, we could not 
confirm that the appropriate patients were studied in all PK 
studies. In addition, in more than 40% of evaluated medicines, 
the severity of hepatic impairment of the studied patients was not 
clearly specified in the SmPC.
A substantial part of information requested in the EMA 
guideline was available in the SmPCs of the medicines in our 
sample that conducted a PK study. For the other medicines, 
the lack of a hepatic impairment study was often justified by 
negligible hepatic clearance of the particular medicinal product 
which is accepted by the EMA (European Medicines Agency, 
2005). Two earlier studies found different results. A study from 
2001 showed that only a few of the 25 studied SmPCs gave 
specific, detailed advice on the use of a medicine in patients with 
hepatic impairment (Anonymous, 2001). Chang and colleagues 
(Chang et al., 2013) observed that a large part of FDA labels 
provided dosing recommendations, but these recommendations 
were in 60% of labels not stratified by severity of hepatic 
impairment while almost all SmPCs in our sample did so. This 
may be explained by different requirements between regulatory 
agencies, and differences between US and EU labelings on 
hepatic impairment have been previously noted (Bjornsson 
et  al., 2015). Considering though that applicants usually conduct 
a single PK study in patients with hepatic impairment that is 
submitted to all regulatory authorities, it is more likely that the 
enhanced information in SmPCs is explained by an improvement 
in the quality of information over time, as these earlier included 
medicines were approved before March 2001, respectively 2011.
TABLE 6 | Overview of safety and dosing recommendations in the SmPCs of 36 medicines, stratified by severity of hepatic impairment.
Mild hepatic impairment Moderate hepatic impairment Severe hepaticimpairment
n % n % n %
Safety recommendations 36 100 36 100 36 100
Can be used (i.e., dose adjustment 
(not) needed)
31 86 21 58 8 22
Use with caution 4 11 8 22 6 17
Outweigh benefits and risks 0 0 0 0 2 6
Not recommended to use 0 0 3 8 10 28
Should not be used 0 0 0 0 2 6
Contraindication 1 3 1 3 3 8
None (not available) 0 0 3 8 5 14
Dosing recommendations 36 100 36 100 36 100
Dose adjustment not needed 33 92 19 53 7 19
Dose adjustment needed 2 6 8 22 4 11
Should not be used/contraindication 1 3 1 3 5 14
None (not available) 0 0 8 22 20 56
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FIGURE 3 | Number and percentage of medicines with clear, ambiguous or unavailable information in SmPCs (n = 36).
TABLE 7 | Results of the assessment of the clinical applicability of the information: examples of clear and ambiguous information described in SmPCs concerning the 
use in patients with hepatic impairment.
Clearly formulated information Ambiguously formulated information 
Patient characteristics
All terms to grade severity of hepatic impairment are 
defined: “Section 4.2: No dose adjustment is required in 
patients with mild hepatic impairment (Child–Pugh A). 
The dose should be reduced to 5 mg once daily in patients 
with moderate hepatic impairment (Child–Pugh B) (see 
sections 4.4 and 5.2). Tofacitinib should not be used in 
patients with severe hepatic impairment (Child–Pugh C) 
(see section 4.3).” (Pfizer Ltd, 2017)
Ambiguous information on type of hepatic disease because of all the different terms used, 
no clear definition: “Section 4.2: Exposure to brivaracetam was increased in adult patients with 
chronic liver disease. (…) A maximum daily dose of 150 mg administered in two divided doses is 
recommended for all stages of hepatic impairment. (…) Section 4.4: There are limited clinical data 
on the use of brivaracetam in patients with pre-existing hepatic impairment. Dose adjustments are 
recommended for patients with hepatic impairment. Section 5.2: A pharmacokinetic study in subjects 
with hepatic cirrhosis (Child–Pugh grades A, B, and C) showed similar increases in exposure to 
brivaracetam irrespective of disease severity (50, 57, and 59%), relative to matched healthy controls.” 
(UCB Pharma SA, 2016)
Definition lacking of terms to stratify severity of impairment: “Section 4.2: No dose adjustment 
is required in patients with mild or moderate hepatic impairment. Baricitinib is not recommended 
for use in patients with severe hepatic impairment. Section 5.2: There was no clinically relevant 
effect on the PK of baricitinib in patients with mild or moderate hepatic impairment. The use of 
baricitinib has not been studied in patients with severe hepatic impairment.” (Eli Lilly, 2017) 
Safety advice in patients with mild/moderate/severe hepatic impairment
Caution is explained: “There are no data in patients with 
severe hepatic impairment (see section 5.2). Rolapitant 
should be used with caution in these patients. If use cannot 
be avoided, patients should be monitored for adverse 
reactions to rolapitant (see section 4.8).” (Tesaro UK 
Ltd, 2017)
Ambiguous safety advice in moderate and severe hepatic impairment: “No dose adjustment 
of dasabuvir is required in patients with mild hepatic impairment (Child–Pugh A). Dasabuvir is not 
recommended in patients with moderate hepatic impairment (Child–Pugh B) (see sections 4.4 and 
4.8). Dasabuvir should not be used in patients with severe hepatic impairment (Child–Pugh C) (see 
section 5.2).” (AbbVie Ltd, 2015) 
Dosing recommendation in patients with mild/moderate/severe hepatic impairment
Dosing advice specified: “Section 4.2: No dose adjustment 
of palbociclib is required for patients with mild or moderate 
hepatic impairment (Child–Pugh classes A and B). For 
patients with severe hepatic impairment (Child–Pugh class 
C), the recommended dose of palbociclib is 75 mg once 
daily on schedule 3/1 (section 4.4, 5.2)” (Pfizer Ltd, 2016) 
Concrete dose recommendation in moderate hepatic impairment lacking: “Section 4.2: No 
dose adjustment is necessary in patients with mild hepatic impairment (Child–Pugh Class A). There 
is limited clinical experience in patients with moderate hepatic impairment (Child–Pugh Class B). 
Caution must be exercised in these patients and dose adjustment may be necessary (see section 
5.2). There is no clinical experience in patients with severe hepatic impairment (Child–Pugh Class 
C); therefore, opicapone is not recommended in these patients (see section 5.2).” (Bial - Portela and 
Ca SA, 2016) 
For clarity, brand names have been replaced by generic medicines names in all examples.
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Prescribing information about patients with severe hepatic 
impairment was often lacking or ambiguously formulated. This 
was probably caused by a lack of clinical data: in the PK study 
of only 14 medicines, patients with severe hepatic impairment 
were included. Previous studies also showed that, with increasing 
severity of hepatic impairment, less prescribing information is 
available (Periáñez-Párraga et al., 2012; Chang et al., 2013). 
If  information on patients with severe hepatic impairment was 
available, it was frequently ambiguously formulated. Vague 
statements such as “not recommended to use” leave it open for 
interpretation whether the medicine is absolutely contraindicated 
and what would be the circumstances of usage. Ambiguous 
formulations such as “use with caution,” “not recommended to 
use,” and “should not be used” were also observed in studies 
examining SmPC recommendations in other clinical areas 
such as renal impairment (Geerts et al., 2012; Beers et al., 2013; 
Salgado et al., 2013; Arguello et al., 2015). This finding should be 
seen in the light of the ethical and practical difficulties faced with 
research in such a vulnerable patient group. Yet, although no 
clinical data are available, measures to be taken by the prescriber 
could still be specified or explained in the SmPC (see Table 7, 
example with rolapitant) as also advised by the EMA (European 
Medicines Agency, 2005).
Another important finding was that the type of hepatic 
disease of patients included in PK studies was not specified in 
the SmPC text, even though specifically requested by the EMA 
guideline (European Medicines Agency, 2005). As shown in 
literature, prescribers other than gastroenterologists often do not 
know which patients with a liver disease need dose adjustments 
or avoidance of certain medicines (Rossi et al., 2008; Nguyen 
et al., 2014) that is possibly caused by the use of the undefined 
term “hepatic impairment.” In the one medicine where the 
type of hepatic disease studied was available in the SmPC, the 
recommendations were ambiguous because different wordings 
were used interchangeably to define the “at-risk population.” The 
study from 2001 already concluded that this “at-risk population” 
was often vaguely described (Anonymous, 2001), so it seems 
little to no progress has been made in this area. We could find the 
information on the hepatic disease that caused the impairment for 
most medicines in the study reports. But contrary to SmPCs and 
EPARs, most of these reports are not (yet) accessible to healthcare 
professionals. The EMA is trying to increase transparency by 
providing access to clinical study data on a website (European 
Medicines Agency, 2019); yet, we noticed we could only find 
study reports for 29% of the medicines. More importantly, it 
appears that regulators are not aware that the hepatic disease 
information is relevant to the healthcare professionals. We 
recommend to include this information in the SmPCs.
The FDA label study (Chang et al., 2013) described the explicit 
use of standardized terminology such as the Child–Pugh score 
as solution for the non-specific phrase “hepatic impairment.” 
In our sample, all dedicated PK studies used this score. An 
important remark to the Child–Pugh classification is that it was 
not intended and validated as a measure to assess the remaining 
capacity of the liver to eliminate medicines (European Medicines 
Agency, 2005). As the guideline also recommends, appropriate 
use of the Child–Pugh classification is important because the 
parameters are not specific of hepatic (elimination) impairment 
(Durand and Valla, 2005; European Medicines Agency, 2005). 
For example, everyone scores 5 points (i.e., class A: “mild hepatic 
impairment”) because that is the minimum score and increases 
in one of the parameters due to other causes (e.g., a bilirubin 
increase due to hemolysis or a prolonged INR due to coumarin 
use) could even result in a “moderate hepatic impairment” 
classification. The guideline provides no further details on 
appropriate use; however, in clinical practice, the Child–Pugh 
score is intended to assess the severity and prognosis of cirrhosis 
(Pugh et al., 1973; Durand and Valla, 2005). Prior literature also 
concluded that hepatic elimination was not significantly impaired 
in a variety of chronic liver diseases unless cirrhosis was present 
(Morgan and McLean, 1995; Verbeeck, 2008). Based on the data 
we found in the study reports, we cannot confirm that the Child–
Pugh classification was used appropriately in all studies. Most of 
the subjects in the PK studies had documented cirrhosis, and the 
Child–Pugh classification was used as intended. In the remaining 
subjects, insufficient details were provided to assess if the hepatic 
elimination capacity was relevantly impaired because there was 
no cirrhosis documented and not even a (chronic) liver disease 
for some. Inappropriate use of the Child–Pugh classification in 
clinical studies may result in an underestimation of the changes 
in PK in patients with hepatic impairment due to cirrhosis. 
Because of its limitations, in further research, alternatives for the 
Child–Pugh classification should be explored.
Strengths and Limitations
We performed an in-depth analysis of the hepatic impairment 
information in authorization documents. Unique to our study is 
the access we had to the non-publicly available part of the study 
reports. We studied a limited number of medicines, making 
comparisons between therapeutic groups or between SmPC 
information over time not possible. Hence, our results cannot be 
generalized to older medicines, especially not those authorized 
before publication of the guideline in 2005. Furthermore, we 
only studied medicines that were granted market authorization 
via a centralized procedure, so results are not necessarily valid 
for medicines authorized through a national or decentralized 
procedure. Nevertheless, in national and decentralized 
procedures, use of the EMA guidelines is also recommended.
Implications
The lack of clear guidance in SmPCs on patients with severe hepatic 
impairment can be challenging for healthcare professionals 
treating these severely ill patients who need medicines but are 
very sensitive to PK and pharmacodynamic alterations. As there 
are practical and ethical issues involved in conducting pre-
registration studies in patients with severe hepatic impairment, it 
would be helpful to collect post-marketing data. Further research 
could explore the potential of registries as information source on 
treatment and outcome in that patient group.
The EMA reinforced in their hepatic impairment guideline the 
need for further research to strengthen and improve the guideline 
(European Medicines Agency, 2005). We recommend to update 
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the guideline on three points. First, the guideline must mention 
that all terms used to describe the severity of hepatic impairment in 
the SmPC should also be defined [e.g., patients with mild hepatic 
impairment (Child–Pugh A)]. Although these definitions are easy to 
include, more than 40% of SmPCs did not provide this information. 
Second, the guideline describes that if precautious use of a medicine 
is advised, SmPCs should also specify measures to be taken by the 
prescriber (European Medicines Agency, 2005). Nevertheless, we 
noticed a high prevalence of ambiguous safety advice that lacked 
such specifications. Therefore, this should be better expressed in 
the guideline and perhaps also better monitored by the regulators. 
Finally, we showed that the main weakness of the guideline is the 
vague term “hepatic impairment” that leaves room for interpretation. 
Pharmaceutical companies and regulators interpret this differently 
resulting in a diversity of patient populations in the PK studies. 
Healthcare professionals as well can have difficulties to interpret 
“hepatic impairment,” possibly resulting in non-optimal advice, 
under- or overdosing. As there is no generally accepted definition 
for the term “hepatic impairment,” its use is not helpful in clinical 
practice (Bjornsson et al., 2015). Therefore, the EMA guideline 
needs to be updated to include a more precise definition. Perhaps, it 
is even better not to use the ambiguous term “hepatic impairment” 
anymore. Instead, we recommend to use the clearly defined term 
“liver cirrhosis” in authorization documents, but also in online drug 
reference works and in the published PK studies. These activities 
may prevent prescribing problems in practice, such as the use 
of inadequate dosages or contraindicated drugs in patients with 
cirrhosis, as demonstrated by Franz et al. (Franz et al., 2013). In the 
Netherlands, the drug-disease interaction “hepatic impairment” has 
been replaced in clinical decision support systems by a new drug-
disease interaction “liver cirrhosis” to better support healthcare 
professionals (Weersink et al., 2016; Weersink et al.,  2018).
CONCLUSION
In this study, we have shown that SmPCs of recently approved 
medicines contain a large part of the information required 
by the EMA guideline on patients with hepatic impairment. 
Although available, the safety advice was often ambiguously 
formulated and therefore not per se clinically applicable. 
Unclear advice on patients with severe hepatic impairment was 
often explained by a lack of research. Information on the type 
of hepatic disease was often lacking in the SmPC but could be 
found in the non-publicly available part of the study report. 
We recommend that such information should be included 
in SmPCs. This information is also needed to judge if the 
Child–Pugh classification was used appropriately, because the 
parameters it includes are not specific of hepatic (elimination) 
impairment. Based on our results, we cannot conclude 
that the appropriate patients were studied in all hepatic 
impairment studies. We specifically recommend to update 
the 2005 EMA guideline to use the clearly defined term “liver 
cirrhosis” instead of “hepatic impairment”. This will support 
pharmaceutical companies in conducting and reporting PK 
studies in the most relevant patients with hepatic disease and 
healthcare professionals when prescribing for these vulnerable 
patients.
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